Quantcast

Simcere Pharmaceutical Group Announces SFDA Approval to Manufacture and Market Palonosetron in China

August 12, 2010

NANJING, China, Aug. 12 /PRNewswire-Asia/ — Simcere Pharmaceutical Group
(“Simcere” or the “Company”) (NYSE: SCR), a leading pharmaceutical company
specializing in the development, manufacturing, and marketing of branded
generic and proprietary pharmaceuticals in China, today announced that its
subsidiary company Simcere Dongyuan Pharmaceutical Co., Ltd. has recently
received SFDA new drug certification and registration approval to manufacture
and market Palonosetron material and injections in China.

Palonosetron is a second generation 5-HT3 antagonist used for the
prevention and control of acute chemotherapy-induced nausea and vomiting
(CINV). According to industry analysis, 5-HT3 antagonists account for 90
percent of the CINV market in China.

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group (NYSE:SCR, Simcere) is a leading
pharmaceutical company specializing in the development, manufacturing, and
marketing of branded generic and proprietary pharmaceuticals in China. In
recent years, Simcere has been focusing its strategy on the development of
innovative pharmaceuticals and first-to-market generics, and has introduced an
innovative anti-cancer medication Endu, a first-to-market medication Sinofuan,
and first-to-market generics such as Bicun and Anxin. Simcere manufactures and
sells antibiotics, anti-cancer medication, stroke management medication and
biopharmaceutical drugs such as vaccines. Simcere concentrates its research
and development efforts on the treatment of diseases with high incidence
and/or mortality rates and for which there is a clear demand for more
effective pharmacotherapy such as cancer, strokes, orthopaedics and infectious
diseases. For more information about Simcere Pharmaceutical Group, please
visit http://www.simcere.com .

    For more information, please contact:

    Investor and Media Contacts:
     Email: ir@simcere.com

    In Nanjing:
     Frank Zhao
     Chief Financial Officer
     Simcere Pharmaceutical Group
     Tel:   +86-25-8556-6666 x8818

    In Beijing:
     Ruirui Jiang
     Brunswick Group
     Tel:   +86-10-6566-2256

    In the United States:
     Kate Tellier
     Brunswick Group
     Tel:   +1-212-333-3810

    In Hong Kong:
     Joseph Lo Chi-Lun
     Brunswick Group
     Tel:   +852-3512-5000

SOURCE Simcere Pharmaceutical Group


Source: newswire



comments powered by Disqus